Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

Inclusion Criteria * Eligible for treatment with dapagliflozin per current FDA-approved indications, including: 1) heart failure (NYHA class II-IV) with reduced left ventricular ejection fraction (\<50%), or 2) type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple CV risk factors, or 3) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, 4) adults with chronic kidney disease at risk of progression as defined by the National Kidney Foundation as estimated GFR \<60 ml/minute/1.73 m2. * Scheduled to undergo ablation of symptomatic paroxysmal or persistent AF prior to date of randomization per current guideline indications. * A glycated hemoglobin level \< 10.5% during the past 6 calendar months prior to consent only in patients with type 2 diabetes mellitus * Age \> 18 years * Existing functional CIED or planned to undergo CIED implant as SOC before or within 24 hours following the AF ablation procedure and prior to randomization date. Exclusion Criteria * Type 1 diabetes mellitus * History of diabetic keto-acidosis * Child Pugh Class C liver disease * Last measured estimated GFR \< 25 ml/minute/1.73 m2 * Pregnancy, plan to become pregnant \<1 year after consent or breast feeding * Current therapy with an SGLT2 inhibitor * Hypersensitivity to dapagliflozin * On heart transplant list or likely to undergo heart transplant * Unwilling or unable to cooperate with the protocol * Participation in other clinical trials (observational registries are allowed with approval). * Unwilling to sign the consent for participation * Life expectancy \<1 year after consent date for any medical condition